Cigna Corporation logo
Cigna Corporation CI
report update icon

Annual report 2025
added 02-26-2026

Cigna Corporation Financial Ratios 2025-2011 | CI

Brief overview of Cigna Corporation's multiples and efficiency

This overview follows the five latest available observations from 2021 through 2025.

Market valuation is represented by P/E 12.79x (median 14.1x), EV/EBITDA 9.45x (median 9.68x), P/S 0.28x (median 0.44x). On average, multiples differ from their five-year medians by only -7.8%. Valuation is near its familiar historical range.

At the current P/E, inverse earnings yield is 7.8%, a useful bridge between price and business earnings.

Current measures of operating quality are ROE 14.3%, ROA 3.8%, ROCE 22.1%. Profitability remains positive and sufficient for normal operations without indicating exceptional efficiency.

Current PEG is 0.11x; the market pays comparatively little per unit of expected growth.

The cash cycle changed only slightly and ended at 30.1 days.

Valuation takeaway

Cigna Corporation's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.

Annual Financial Ratios Cigna Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

12.8 24.3 19.0 13.0 14.1 8.6 13.1 18.7 22.7 19.9 16.3 13.4 16.6 10.3 9.1

P/S

0.3 0.3 0.5 0.5 0.4 0.5 0.4 1.0 1.2 0.9 0.9 0.8 0.8 0.6 0.5

EPS

22.3 12.2 17.6 21.7 15.9 23.2 13.6 10.7 8.9 7.3 - - - - -

EV (Enterprise Value)

185 B 190 B 197 B 181 B 179 B 168 B 173 B 158 B 95.8 B 82.8 B 79.3 B 73.3 B 68.2 B 60.7 B 54.7 B

EBITDA per Share

45.5 44.5 39.6 38.1 33.6 30.9 31.5 - - - - - 9.93 - -

EV/EBITDA

9.5 9.7 - - - - - - 9.7 - -

PEG

- 0.11 0.54 1.13 0.89 -1.89 6.51 0.26 -2.25 0.63 -14.92

P/B

1.8 2.0 2.1 2.0 1.6 1.5 1.5 1.2 3.7 2.7 2.8 2.6 2.3 1.7 1.4

P/CF

7.9 8.0 8.3 10.2 10.6 7.1 7.1 15.2 14.0 10.4 15.5 18.5 127.5 8.6 11.3

ROE %

14.28 8.37 11.17 15.18 11.54 16.91 11.26 6.43 16.29 13.60 17.39 19.48 13.95 16.61 15.90

ROA %

3.77 2.20 3.38 4.71 3.50 5.46 3.28 1.72 3.62 3.15 3.67 3.76 2.72 3.02 2.60

ROCE %

22.06 22.95 18.46 18.91 16.90 16.24 17.81 - - - - - - - -

Current Ratio

1.4 1.4 1.4 1.5 1.4 1.5 1.4 - - - - - - - -

DSO

35.2 31.0 32.7 32.6 28.6 26.1 25.2 120.1 82.7 87.9 101.3 102.8 104.7 100.7 22.5

DIO

11.9 12.3 14.2 12.4 10.7 10.3 10.2 - - - - - - - -

DPO

16.9 17.8 22.3 21.1 18.8 18.6 17.7 - - - - - - - -

Operating Cycle

47.1 43.3 46.9 45.1 39.3 36.3 35.4 - - - - - - - -

Cash Conversion Cycle

30.1 25.5 24.6 24.0 20.4 17.7 17.7 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Cigna Corporation

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

4.96 4.28 - 9.07 4.94 3.76 - 4.84 4.3 3.33 - 3.81 4.77 3.19 2.63 3.6 3.73 3.61 0.56 3.18 3.32 3.78 1.09 2.25 3.2 2.34 - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

18.59 18.71 12.23 15.68 12.96 12.55 8.91 11.69 11.02 11.49 8.64 10.79 11.00 10.61 11.28 9.47 8.37 7.23 6.44 8.03 6.14 4.18 1.94 - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

5.74 5.53 3.51 4.57 2.91 3.87 2.79 3.69 3.53 3.70 2.80 3.42 3.39 3.17 3.28 2.75 2.39 2.01 1.72 2.06 1.56 1.03 0.43 - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

18.92 19.22 14.68 19.52 19.60 18.82 13.31 17.50 16.85 17.69 13.53 18.21 18.71 18.23 14.37 17.13 15.21 13.27 8.78 8.78 6.02 3.19 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.4 1.4 1.4 1.5 - 1.4 1.4 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.3 - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

33.8 34.2 - 17.4 16.1 32.2 - 32.7 30.7 28.7 - 27.2 28.3 27.2 25.6 25.4 25.2 25.5 66.8 83.4 83.2 54.5 13.5 - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

11.9 13.0 - 5.8 5.1 11.1 - 9.2 9.4 10.2 - 10.8 11.3 11.0 - 9.9 9.7 10.4 - 427.6 419.9 248.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

21.1 21.9 - 9.9 9.7 20.3 - 17.1 17.8 18.6 - 18.8 19.5 19.9 - 18.9 18.6 17.9 - 661.8 649.9 370.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

45.7 47.3 - 23.2 21.2 43.3 - 41.9 40.1 38.9 - 38.0 39.6 38.2 25.6 35.2 34.9 35.9 66.8 511.0 503.2 302.4 13.5 - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

24.7 25.3 - 13.3 11.5 22.9 - 24.7 22.4 20.3 - 19.2 20.1 18.2 25.6 16.3 16.3 17.9 66.8 -150.8 -146.7 -67.6 13.5 - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Cigna Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Health care industry

Issuer Price % 24h Market Cap Country
NovoCure Limited NovoCure Limited
NVCR
- - $ 1.93 B jerseyJersey
Triple-S Management Corporation Triple-S Management Corporation
GTS
- 0.28 % $ 847 M usaUSA
Magellan Health, Inc. Magellan Health, Inc.
MGLN
- -0.19 % $ 2.49 B usaUSA
Anthem Anthem
ANTM
- -2.32 % $ 107 B usaUSA
Molina Healthcare Molina Healthcare
MOH
- - $ 10.8 B usaUSA
Centene Corporation Centene Corporation
CNC
- - $ 31.8 B usaUSA
CVS Health Corporation CVS Health Corporation
CVS
$ 106.79 -0.88 % $ 135 B usaUSA
UnitedHealth Group Inc. UnitedHealth Group Inc.
UNH
$ 417.79 -0.68 % $ 379 B usaUSA
Humana Humana
HUM
$ 383.44 -1.48 % $ 46.2 B usaUSA